Connection

Chadrick Denlinger to Camptothecin

Back to Details
This is a "connection" page, showing publications Chadrick Denlinger has written about Camptothecin.
Chadrick Denlinger
Connection Strength
0.121
Camptothecin
  1. Phase II study of selumetinib (AZD6244, ARRY-142886) plus irinotecan as second-line therapy in patients with K-RAS mutated colorectal cancer. Cancer Chemother Pharmacol. 2015 Jan; 75(1):17-23.
    View in: PubMed
    Score: 0.121
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.